EUVIMEDEUVIMED entdecken
Open Access

Gene, RNA, and ASO-based therapeutic approaches in Cystic Fibrosis

Normand E Allaire, Uta Griesenbach, Batsheva Kerem, John D Lueck, Noemie Stanleigh, Yifat S Oren

Journal of Cystic Fibrosis · 2023-03 · 22 · S39-S44

DOI: 10.1016/j.jcf.2022.12.016 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cystic Fibrosis, 2023-03. Verfasst von Normand E Allaire und 5 weiteren Autor:innen. Beteiligte Einrichtung: Cystic Fibrosis Foundation Laboratory, Lexington MA, USA. Electronic address: nallaire@cff.org. Hauptthemen laut MEDLINE: Cystic Fibrosis. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, Israel Science Foundation, Ministry of Science and Technology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Most people with Cystic Fibrosis (PwCF) harbor Cystic Fibrosis Transmembrane Conductance (CFTR) mutations that respond to highly effective CFTR modulators (HEM); however, a small fraction of non-responsive variants will require alternative approaches for treatment. Furthermore, the long-term goal to develop a cure for CF will require novel therapeutic strategies. Nucleic acid-based approaches offer the potential to address all CF-causing mutations and possibly a cure for all PwCF. In this minireview, we discuss current knowledge, recent progress, and critical questions surrounding the topic of Gene-, RNA-, and ASO-based therapies for the treatment of Cystic Fibrosis (CF).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cystic FibrosisHumansCystic Fibrosis Transmembrane Conductance RegulatorRNAMutationGenetic Therapy

Stichwörter der Autor:innen

ASOCystic FibrosisDeliveryGeneRNATherapeutic

Substanzen

Cystic Fibrosis Transmembrane Conductance RegulatorRNA

Autor:innen und Institutionen

  • Cystic Fibrosis Foundation Laboratory, Lexington MA, USA. Electronic address: nallaire@cff.org.
  • National Heart and Lung Institute, Imperial College London and the UK Respiratory Gene Therapy Consortium, UK.
  • Department of Genetics, The Life Sciences Institute, Hebrew University, Jerusalem, Israel.
  • Department of Pharmacology and Physiology, University of Rochester Medical Center, Rochester, NY, USA.
  • SpliSenseTherapeutics, Biohouse Labs, Haddasah Ein Karem, Jerusalem, IL.

Förderung

  • NHLBI NIH HHS
  • Israel Science Foundation
  • Ministry of Science and Technology
  • National Institutes of Health
  • Cystic Fibrosis Foundation
  • Boehringer Ingelheim

Zitieren

APA

Allaire, N. E., Griesenbach, U., Kerem, B., Lueck, J. D., Stanleigh, N., & Oren, Y. S. (2023). Gene, RNA, and ASO-based therapeutic approaches in Cystic Fibrosis. Journal of Cystic Fibrosis, 22, S39-S44. https://doi.org/10.1016/j.jcf.2022.12.016

Vancouver

Allaire NE, Griesenbach U, Kerem B, Lueck JD, Stanleigh N, Oren YS. Gene, RNA, and ASO-based therapeutic approaches in Cystic Fibrosis. Journal of Cystic Fibrosis. 2023;22:S39-S44. doi:10.1016/j.jcf.2022.12.016

BibTeX
@article{Allaire2023,
  author = {Allaire, Normand E and Griesenbach, Uta and Kerem, Batsheva and Lueck, John D and Stanleigh, Noemie and Oren, Yifat S},
  title = {Gene, RNA, and ASO-based therapeutic approaches in Cystic Fibrosis},
  journal = {Journal of Cystic Fibrosis},
  year = {2023},
  volume = {22},
  pages = {S39--S44},
  doi = {10.1016/j.jcf.2022.12.016}
}
Kostenlos starten →